South Korea · Delayed Price · Currency is KRW JW Lifescience Statistics
Total Valuation
JW Lifescience has a market cap or net worth of KRW 183.80 billion. The enterprise value is 213.05 billion.
| Market Cap | 183.80B |
| Enterprise Value | 213.05B |
Important Dates
The last earnings date was Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
JW Lifescience has 15.48 million shares outstanding. The number of shares has decreased by -0.01% in one year.
| Current Share Class | 15.48M |
| Shares Outstanding | 15.48M |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 0.76% |
| Float | 8.56M |
Valuation Ratios
The trailing PE ratio is 3.71.
| PE Ratio | 3.71 |
| Forward PE | n/a |
| PS Ratio | 0.75 |
| PB Ratio | 0.88 |
| P/TBV Ratio | 1.38 |
| P/FCF Ratio | 4.15 |
| P/OCF Ratio | 3.26 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.23, with an EV/FCF ratio of 4.81.
| EV / Earnings | 4.31 |
| EV / Sales | 0.87 |
| EV / EBITDA | 3.23 |
| EV / EBIT | 4.34 |
| EV / FCF | 4.81 |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.13 |
| Quick Ratio | 0.73 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 1.04 |
| Debt / FCF | 1.28 |
| Interest Coverage | 18.18 |
Financial Efficiency
Return on equity (ROE) is 26.50% and return on invested capital (ROIC) is 9.83%.
| Return on Equity (ROE) | 26.50% |
| Return on Assets (ROA) | 8.17% |
| Return on Invested Capital (ROIC) | 9.83% |
| Return on Capital Employed (ROCE) | 16.83% |
| Revenue Per Employee | 820.33M |
| Profits Per Employee | 166.62M |
| Employee Count | 297 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 5.90 |
Taxes
In the past 12 months, JW Lifescience has paid 12.55 billion in taxes.
| Income Tax | 12.55B |
| Effective Tax Rate | 20.24% |
Stock Price Statistics
The stock price has increased by +4.55% in the last 52 weeks. The beta is 0.41, so JW Lifescience's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | +4.55% |
| 50-Day Moving Average | 12,155.40 |
| 200-Day Moving Average | 11,484.95 |
| Relative Strength Index (RSI) | 52.41 |
| Average Volume (20 Days) | 32,957 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, JW Lifescience had revenue of KRW 243.64 billion and earned 49.48 billion in profits. Earnings per share was 3,195.76.
| Revenue | 243.64B |
| Gross Profit | 66.27B |
| Operating Income | 37.46B |
| Pretax Income | 62.04B |
| Net Income | 49.48B |
| EBITDA | 54.37B |
| EBIT | 37.46B |
| Earnings Per Share (EPS) | 3,195.76 |
Balance Sheet
The company has 27.29 billion in cash and 56.54 billion in debt, giving a net cash position of -29.24 billion or -1,888.62 per share.
| Cash & Cash Equivalents | 27.29B |
| Total Debt | 56.54B |
| Net Cash | -29.24B |
| Net Cash Per Share | -1,888.62 |
| Equity (Book Value) | 209.99B |
| Book Value Per Share | 13,561.24 |
| Working Capital | 11.68B |
Cash Flow
In the last 12 months, operating cash flow was 56.39 billion and capital expenditures -12.09 billion, giving a free cash flow of 44.30 billion.
| Operating Cash Flow | 56.39B |
| Capital Expenditures | -12.09B |
| Free Cash Flow | 44.30B |
| FCF Per Share | 2,861.15 |
Margins
Gross margin is 27.20%, with operating and profit margins of 15.38% and 20.31%.
| Gross Margin | 27.20% |
| Operating Margin | 15.38% |
| Pretax Margin | 25.46% |
| Profit Margin | 20.31% |
| EBITDA Margin | 22.31% |
| EBIT Margin | 15.38% |
| FCF Margin | 18.18% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 4.26%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 4.26% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 15.65% |
| Buyback Yield | 0.01% |
| Shareholder Yield | 4.27% |
| Earnings Yield | 26.92% |
| FCF Yield | 24.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 20, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Apr 20, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
JW Lifescience has an Altman Z-Score of 2.88 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.88 |
| Piotroski F-Score | 5 |